BR100 Increased By (0.54%)
BR30 Increased By (0.7%)
KSE100 Increased By (0.58%)
KSE30 Increased By (0.63%)
AGHA 6.43 Increased By ▲ 0.05 (0.78%)
BECO 4.38 Increased By ▲ 0.03 (0.69%)
BML 63.50 Increased By ▲ 0.95 (1.52%)
BOP 31.52 Increased By ▲ 0.13 (0.41%)
CNERGY 11.86 Increased By ▲ 0.13 (1.11%)
CSIL 5.99 Increased By ▲ 0.08 (1.35%)
FCCL 61.90 Increased By ▲ 0.19 (0.31%)
FFL 14.86 Increased By ▲ 0.07 (0.47%)
FNEL 1.30 Increased By ▲ 0.06 (4.84%)
KEL 6.38 Increased By ▲ 0.06 (0.95%)
KOSM 5.94 Increased By ▲ 0.04 (0.68%)
LOTCHEM 24.68 Decreased By ▼ -0.01 (-0.04%)
MLCF 104.50 Increased By ▲ 0.57 (0.55%)
NBP 174.85 Increased By ▲ 1.53 (0.88%)
NCPL 51.60 Decreased By ▼ -0.23 (-0.44%)
NPL 54.50 Increased By ▲ 0.47 (0.87%)
OGDC 318.00 Increased By ▲ 2.13 (0.67%)
PACE 9.40 Increased By ▲ 0.14 (1.51%)
PAEL 35.68 Increased By ▲ 0.10 (0.28%)
PIBTL 13.90 Increased By ▲ 0.24 (1.76%)
PPL 227.10 Increased By ▲ 1.03 (0.46%)
PRL 81.26 Increased By ▲ 0.98 (1.22%)
PTC 47.24 Increased By ▲ 0.60 (1.29%)
SSGC 24.00 Increased By ▲ 0.18 (0.76%)
TBL 9.37 Increased By ▲ 0.13 (1.41%)
TELE 7.64 Increased By ▲ 0.09 (1.19%)
TPL 24.87 Increased By ▲ 0.33 (1.34%)
TPLP 13.19 Increased By ▲ 0.20 (1.54%)
TREET 26.15 Increased By ▲ 0.17 (0.65%)
TRG 53.80 Increased By ▲ 0.47 (0.88%)
Business & Finance

Moderna CEO says world faces 2022 COVID vaccine production surplus

  • "Next year there is going to be way too many vaccines for people on the planet," he said.
  • He added that Moderna was working hard to have a booster vaccine against COVID-19 variants approved by the northern hemisphere late summer or early autumn.
Published Updated
By

GENEVA: Manufacturers should focus on producing as many vaccines as possible this year, but the world faces a potential surplus next year in capacity, Moderna's CEO said on Friday.

Speaking at a virtual event on vaccine manufacturing, Stephane Bancel said that additional technology transfers might dent their ability to meet production targets. Moderna is on track to make up to 1 billion doses this year and 1.4 billion next year, he said.

"Next year there is going to be way too many vaccines for people on the planet," he said.

He added that Moderna was working hard to have a booster vaccine against COVID-19 variants approved by the northern hemisphere late summer or early autumn.

Bancel, asked about shortages of workers at the Lonza factory at Visp in the Swiss canton of Valais, which has a licence to make ingredients for its COVID-19 vaccine, but was confident that Lonza would close the gap there soon.

He also said that Moderna was in talks with the COVAX vaccine-sharing facility which is providing doses to lower income countries, adding: "I hope we are in the final stretch to get an agreement with COVAX."

Comments

Comments are closed for this article.